Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

News, features, and commentary about cancer-related issues ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

Having a prostate-specific antigen (PSA) test result above 4.0 ng/mL is considered abnormal and it is worth closer testing, a physician said yesterday, as he suggested individuals with a family ...

NEW ORLEANS - Ochsner MD Anderson Cancer Center will be the first in the South to offer Biology-Guided Radiotherapy, joining ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Adelaide newsreader Will McDonald has managed his aggressive stage 4 prostate cancer for six years now, although he knows the intensive drug regime he is on, while doing the trick for now, won’t last ...